mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition

BRAF inhibitors (BRAFi) and the combination therapy of BRAF and MEK inhibitors (MEKi) were recently approved for therapy of metastatic melanomas harbouring the oncogenic BRAFV600 mutation. Although these therapies have shown pronounced therapeutic efficacy, the limited durability of the response ind...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncotarget
Main Authors: Xue, Gongda, Kohler, Reto, Tang, Fengyuan, Hynx, Debby, Wang, Yuhua, Orso, Francesca, Prêtre, Vincent, Ritschard, Reto, Hirschmann, Petra, Cron, Peter, Roloff, Tim, Dummer, Reinhard, Mandalà, Mario, Bichet, Sandrine, Genoud, Christel, Meyer, Alexandra G., Muraro, Manuele G., Spagnoli, Giulio C., Taverna, Daniela, Rüegg, Curzio, Merghoub, Taha, Massi, Daniela, Tang, Huifang, Levesque, Mitchell P., Dirnhofer, Stephan, Zippelius, Alfred, Hemmings, Brian A., Wicki, Andreas
Format: Artigo
Sprog:Inglês
Udgivet: Impact Journals LLC 2017
Fag:
Priority Research Paper
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5642473/
https://ncbi.nlm.nih.gov/pubmed/29050198
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18213
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker